Korys is a venture capital fund based in Brussels, established by the Colruyt family. The fund's name is derived from the Latin word for hazelnut tree, "Corylus," linked to the Colruyt name. Korys targets investments in biotech and agritech companies at the series C stage, with notable investments like Aphea.Bio. The firm's strategy includes a balanced portfolio of stocks, bonds, private equity, and support for small and medium-sized enterprises. Korys focuses on long-term investments that aim to generate meaningful, sustainable impacts on people and the planet while achieving good returns.
